Edwards Lifesciences (NYSE: EW) will not acquire JenaValve after FTC injunction

Rhea-AI Filing Summary

Edwards Lifesciences Corporation reports that the United States District Court for the District of Columbia has granted the U.S. Federal Trade Commission’s motion for an injunction blocking Edwards’ proposed acquisition of JenaValve Technology, Inc. As a direct result of this court action, Edwards states that it will not acquire JenaValve.

The update is presented as an other event and is based on a company press release dated January 9, 2026, which is attached as an exhibit. The filing focuses on the legal outcome affecting this specific transaction and does not provide additional financial figures or broader business updates.

Positive

• None.

Negative

• Court injunction blocks a strategic acquisition: The U.S. District Court for the District of Columbia granted the FTC’s motion for an injunction, leading Edwards Lifesciences to terminate its planned acquisition of JenaValve Technology, Inc., eliminating anticipated strategic benefits from that transaction.

Insights

Healthcare M&A and regulatory analyst

A U.S. court injunction, sought by the FTC, stops Edwards’ planned JenaValve acquisition.

The filing explains that the U.S. District Court for the District of Columbia granted the Federal Trade Commission’s motion for an injunction against Edwards Lifesciences’ proposed acquisition of JenaValve Technology, Inc. Edwards states that, as a result, it will not complete this acquisition. This shifts the company’s previously planned path for expanding in JenaValve’s product and technology areas.

The development highlights regulatory scrutiny around this transaction, with the FTC successfully obtaining court relief to block it. While the filing does not quantify financial impacts or synergies that are now foregone, it confirms that any strategic benefits Edwards expected from owning JenaValve will not materialize via this deal structure. Future disclosures in company reports may outline any alternative plans in the affected business segment.

0001099800false00010998002026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 9, 2026

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-15525

36-4316614

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

One Edwards Way

Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 250-2500

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $1.00 per share			EW			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Other Events.

On January 9, 2026 Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the United States District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission for an injunction blocking the Company’s proposed acquisition of JenaValve Technology, Inc (“JenaValve”). As a result, the Company will not acquire JenaValve.

A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)						Exhibits
99.1						Press Release of Edwards Lifesciences Corporation, dated as of January 9, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						EDWARDS LIFESCIENCES CORPORATION
						By:			/s/ Mark D. Peterson
									Mark D. Peterson
Date: January 9, 2026									Corporate Vice President, General Counsel

3

FAQ

What did Edwards Lifesciences (EW) disclose in this 8-K filing?

Edwards Lifesciences disclosed that the United States District Court for the District of Columbia granted the U.S. Federal Trade Commission’s motion for an injunction blocking Edwards’ proposed acquisition of JenaValve Technology, Inc., and that Edwards will not acquire JenaValve as a result.

What is the outcome of Edwards Lifesciences’ proposed acquisition of JenaValve Technology, Inc.?

The filing states that, because the court granted the FTC’s motion for an injunction blocking the transaction, Edwards Lifesciences will not acquire JenaValve Technology, Inc.

Which regulator opposed the Edwards Lifesciences–JenaValve deal?

The filing explains that the U.S. Federal Trade Commission sought an injunction against the proposed acquisition, and the United States District Court for the District of Columbia granted the FTC’s motion.

Does the 8-K for Edwards Lifesciences (EW) include the full press release about the blocked JenaValve acquisition?

Yes. The company states that a press release dated January 9, 2026, describing the injunction and blocked acquisition is attached as Exhibit 99.1 and incorporated by reference for informational purposes under Item 7.01.

Is the information about the JenaValve injunction considered filed for liability purposes?

No. Edwards specifies that the information in Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.

What exhibits are included with this Edwards Lifesciences 8-K?

The exhibits listed are 99.1, the press release dated January 9, 2026, regarding the injunction and acquisition outcome, and 104, the cover page interactive data file embedded within the Inline XBRL document.